Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 m

Event · Earnings
Original reporting
Published Aug 13, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RKDA
Bearish
medium confidence
Mentioned
$RKDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RKDABearishMed
01

Why it matters

The key tradable elements are liquidity (cash and short-term investments), loss trajectory, and balance-sheet liabilities tied to warrants/options and PIPE-related valuation effects.

02

Market read

For RKDA, the filing provides fresh liquidity and loss metrics plus PIPE-related accounting impacts that can affect dilution and near-term risk pricing.

03

What to watch

Non-cash items (warrant/option fair value, PIPE valuation loss) may overstate underlying operating deterioration; traders should separate cash burn from accounting remeasurement.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 13, 2026

Background

This is an SEC Form 8-K (Item 2.02) with Exhibit 99.2 financial statements for Arcadia Biosciences through June 30, 2026.

Company-level read

Ticker impact

$RKDABearishMedium confidence
Context

Arcadia reported June 30, 2026 results in an 8-K, including cash of $4.178m and a six-month net loss of $10.651m.

Expected impact

Likely bearish bias for risk/liquidity traders, with volatility around financing/dilution expectations.

Evidence & confidence

The 8-K discloses cash increase to $4.178m from $0.259m, but also shows large non-cash valuation losses and a $10.651m net loss over six months, plus warrant/option liabilities rising to $3.614m.

Market effects

Adds another datapoint on ongoing financing needs and valuation volatility in small-cap biotech.

No clear regional spillover indicated.

Limited, company-specific disclosure.

Counterpoint

The cash balance jump suggests the June 2026 PIPE may extend runway, potentially reducing immediate going-concern fears despite losses.

Key entities

  • Arcadia Biosciences, Inc.

    Subject of the 8-K, reporting unaudited balance sheet, operations, and cash flows through June 30, 2026.

  • June 2026 PIPE

    Disclosed as a source of proceeds ($4.0m) and associated valuation loss on the PIPE in the income statement.

Related articles

$RKDAMed

Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --

$RKDAMedAI 9/10

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

$BABAMed

Alibaba and Temu cut marketing as AI engines start handing out coupons

Alibaba and Temu's parent company PDD reduced marketing spending by 38% and 17% respectively, with Alibaba's revenue up 10% and Temu's flat. Both companies shifted focus to AI and advertising. Alibaba's cloud revenue rose 53%, while Temu's advertising income overtook commissions. AI assistants now provide coupon codes directly, potentially impacting coupon sites.